MedPath

Sirion Therapeutics, Inc.

Sirion Therapeutics, Inc. logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
2005-01-01
Employees
101
Market Cap
-
Website
https://www.siriontherapeutics.com

Clinical Trials

15

Active:0
Completed:15

Trial Phases

2 Phases

Phase 2:4
Phase 3:11

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials

Phase 3
11 (73.3%)
Phase 2
4 (26.7%)

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

Phase 3
Completed
Conditions
Inflammation
Interventions
Other: Placebo
First Posted Date
2008-02-15
Last Posted Date
2011-07-01
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
120
Registration Number
NCT00616993
Locations
🇺🇸

Eye Associates of Fort Myers, Fort Myers, Florida, United States

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)

Phase 3
Completed
Conditions
Inflammation
Interventions
Other: Placebo
First Posted Date
2008-02-15
Last Posted Date
2011-06-30
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
120
Registration Number
NCT00616070
Locations
🇺🇸

Charlotte Eye, Ear, Nose & Throat, Charlotte, North Carolina, United States

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)

Phase 3
Completed
Conditions
Dry Eye Syndromes
First Posted Date
2007-10-25
Last Posted Date
2007-10-25
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00549289
Locations
🇺🇸

Clayton Eye Center, Morrow, Georgia, United States

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)

Phase 3
Completed
Conditions
Dry Eye Syndromes
First Posted Date
2007-10-23
Last Posted Date
2011-07-01
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00548301
Locations
🇺🇸

Eye Center Northeast, Bangor, Maine, United States

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)

Phase 3
Completed
Conditions
Dry Eye Syndromes
First Posted Date
2007-07-17
Last Posted Date
2011-07-01
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00502073
Locations
🇺🇸

Eye Center Northeast, Bangor, Maine, United States

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.